PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries Ltd (formerly Sun Techno Overseas Ltd) reported audited FY25 results with an unmodified audit opinion from Rishi Sekhri and Associates. Revenue from operations fell sharply to Rs 83.84 lakhs in FY25 from Rs 238.15 lakhs in FY24, a drop of about 65% year-on-year. The company swung to a net loss of Rs 29.27 lakhs in FY25, compared to a profit of Rs 193.07 lakhs in FY24. However, the March 2025 quarter showed a recovery with revenue of Rs 135.23 lakhs and a net profit of Rs 117.78 lakhs. The company raised Rs 3,570 lakhs through share issuance, turning its other equity from negative Rs 873.99 lakhs to positive Rs 2,666.74 lakhs. Operating cash flow was negative at Rs 109.10 lakhs versus positive Rs 196.59 lakhs in the previous year.
Despite a strong March quarter, the full-year performance shows declining revenue and a return to losses with negative operating cash flow, which may concern shareholders. However, the fresh equity infusion has strengthened the balance sheet and eliminated negative reserves, providing a more stable equity base going forward.